zuclopenthixol dihydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
zuclopenthixol dihydrochloride: clinical details
Prescribing considerations
- Confirm indication and previous response to antipsychotic treatment; the tablets are not licensed for dementia-related behavioural disturbance.
- Assess cardiovascular disease, bradycardia, QT risk, electrolyte disturbance, VTE risk, epilepsy, Parkinson's disease, respiratory disease, renal or hepatic impairment and anticholinergic vulnerability.
- Older or frail people are more susceptible to sedation, hypotension, confusion and temperature disturbance.
- Avoid abrupt withdrawal and routine antipsychotic polypharmacy.
- Review lactose-related hereditary disorders and potential gastrointestinal effects of hydrogenated castor oil.
Contraindications and cautions
- Hypersensitivity to zuclopenthixol or an excipient
- Circulatory collapse
- Depressed consciousness from any cause, including alcohol, opioid or barbiturate intoxication
- Coma
Monitoring
- Assess efficacy, adherence, sedation, postural symptoms, extrapyramidal effects and tardive dyskinesia.
- Monitor weight and appetite; review glucose control, particularly in diabetes.
- Consider ECG and electrolyte assessment where cardiovascular or QT-prolongation risks exist.
- Remain alert for venous thromboembolism, swallowing impairment and neuroleptic malignant syndrome.
- Obtain a blood count if persistent infection develops; consider liver assessment and serum-level monitoring in compromised hepatic function.
Clinical pharmacology
A thioxanthene antipsychotic acting principally through dopamine D1 and D2 receptor blockade. Metabolism includes sulphoxidation, N-dealkylation and glucuronidation; faecal excretion predominates.
Formulation and product differences
- The selected product is an oral film-coated tablet containing zuclopenthixol as the dihydrochloride salt.
- The tablets contain lactose and hydrogenated castor oil; appearance and light-storage requirements differ between tablet strengths.
- Other zuclopenthixol salt formulations have different release characteristics and must not be treated as interchangeable with these oral tablets.
zuclopenthixol dihydrochloride preparations and strengths
Tablet
Route: Oral
Strengths: 25 mg
zuclopenthixol dihydrochloride interactions
Check all prescribed, over-the-counter and recreational substances with a pharmacist or prescriber. Important examples include:
Alcohol, opioids, sedatives and other central nervous system depressants
Sedation and impaired alertness may be increased.
Medicines that prolong the QT interval
Antiarrhythmics, some antibiotics, antihistamines and other antipsychotics can increase the risk of dangerous heart rhythms.
Diuretics causing low potassium or magnesium
Electrolyte disturbance can further increase the risk of QT prolongation and arrhythmia.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.